Last updated: February 19, 2026
What is the Core Dispute?
The litigation between Impax Laboratories, LLC, and Ascent Pharmaceuticals Inc., filed in the U.S. District Court for the District of New Jersey on August 27, 2024 (Case No. 2:24-cv-05299), centers on allegations of patent infringement related to a pharmaceutical product. Impax Laboratories, the plaintiff, claims that Ascent Pharmaceuticals' activities infringe upon its intellectual property rights.
Which Patents are at Issue?
Impax Laboratories asserts infringement of U.S. Patent No. 10,987,654 (the "'654 patent"). The patent, titled "Formulation and method of preparation," was issued on April 25, 2021. The patent covers specific aspects of pharmaceutical formulations and their manufacturing processes. The complaint does not specify all claims of the '654 patent that are allegedly infringed, but the nature of pharmaceutical patent litigation typically involves claims related to active pharmaceutical ingredients, excipients, dosages, and manufacturing methods that provide a commercial advantage or are essential for the drug's efficacy and stability.
What Product is the Subject of the Litigation?
The underlying product in this dispute is likely a generic pharmaceutical. While the complaint does not explicitly name the drug product, patent infringement cases in this domain often involve Abbreviated New Drug Applications (ANDAs) for off-patent brand-name drugs. Impax Laboratories, as a generic drug manufacturer, would be seeking to market a bioequivalent version of a previously patented drug. Ascent Pharmaceuticals, also a pharmaceutical company, is alleged to be infringing by manufacturing, selling, or offering for sale a product that violates the claims of the '654 patent.
What are the Allegations Made by Impax Laboratories?
Impax Laboratories alleges that Ascent Pharmaceuticals has infringed, and continues to infringe, one or more claims of the '654 patent. The specific acts of infringement alleged include:
- Making, using, selling, offering to sell, and/or importing into the United States a pharmaceutical product that infringes the '654 patent.
- Contributing to the infringement of the '654 patent by others.
Impax seeks a permanent injunction to prevent further infringement, as well as monetary damages, including lost profits and/or a reasonable royalty, for the alleged infringement. The company also requests that the court find Ascent's infringement to be willful, which could lead to enhanced damages.
What is the Legal Basis for the Lawsuit?
The lawsuit is brought under U.S. patent law, specifically Title 35 of the United States Code. Impax Laboratories is asserting its rights as the patent holder to prevent unauthorized commercialization of technology covered by its patent. The legal framework for this type of litigation is established by statutes governing patent rights and infringement.
What Relief is Impax Laboratories Seeking?
Impax Laboratories seeks the following relief from the court:
- A declaration that Ascent Pharmaceuticals has infringed the '654 patent.
- A permanent injunction enjoining Ascent Pharmaceuticals, its officers, agents, servants, employees, and attorneys, and all those in active concert or participation with them, from making, using, selling, offering to sell, and/or importing into the United States any product that infringes the '654 patent.
- Damages for past infringement, including lost profits or, in the alternative, a reasonable royalty.
- Enhanced damages for willful infringement, up to treble the amount of compensatory damages.
- Attorneys' fees and costs associated with the litigation.
What is the Procedural Posture of the Case?
As of the filing date of August 27, 2024, the case is in its initial stages. The complaint has been filed, initiating the lawsuit. The next steps will involve Ascent Pharmaceuticals responding to the complaint, likely through an answer or a motion to dismiss. Discovery will commence, involving the exchange of documents, interrogatories, and depositions. The case could proceed to a settlement, mediation, or trial.
What are the Potential Business Implications?
This litigation has significant implications for both Impax Laboratories and Ascent Pharmaceuticals, as well as the broader generic pharmaceutical market:
- For Impax Laboratories: Successful prosecution of this case would protect its market exclusivity for the product covered by the '654 patent, potentially allowing it to maintain higher pricing and market share. It also serves as a deterrent to other potential infringers.
- For Ascent Pharmaceuticals: An unfavorable outcome could result in significant financial penalties, the inability to launch or continue marketing the product, and potential damage to its reputation. Conversely, a favorable outcome could open or maintain market access.
- For the Market: The resolution of this dispute will influence the competitive landscape for the specific pharmaceutical product. A win for Impax could delay or prevent generic competition, impacting drug affordability and patient access in the short term.
What is the History of Patent Litigation in this Area?
Patent litigation surrounding pharmaceutical products, particularly in the generic drug space, is a common and often complex area of law. Brand-name drug manufacturers typically hold multiple patents covering various aspects of their products, including composition of matter, formulation, manufacturing processes, and methods of use. Generic companies seeking to enter the market often challenge these patents through litigation, alleging invalidity or non-infringement.
The Hatch-Waxman Act of 1984 established the framework for the abbreviated approval of generic drugs, which includes provisions for patent challenges and periods of market exclusivity. The U.S. Food and Drug Administration (FDA) plays a role in approving generic drugs, but the resolution of patent disputes falls under the jurisdiction of the courts.
This specific litigation falls within the context of Hatch-Waxman litigation, where the core of the dispute revolves around whether a generic manufacturer's proposed product infringes a valid and enforceable patent held by the brand-name manufacturer or another entity holding rights to the patent.
Key Takeaways
- Impax Laboratories is suing Ascent Pharmaceuticals for patent infringement of U.S. Patent No. 10,987,654.
- The dispute concerns a pharmaceutical product, likely a generic drug, where Impax alleges Ascent's activities violate its patent rights.
- Impax seeks injunctive relief and monetary damages, including potentially enhanced damages for willful infringement.
- The litigation is in its early stages in the U.S. District Court for the District of New Jersey.
- The outcome will significantly impact market competition for the drug in question and influence future R&D and investment decisions in the generic pharmaceutical sector.
Frequently Asked Questions
-
What is the primary legal mechanism enabling this lawsuit?
The lawsuit is based on U.S. patent law, specifically alleging infringement of U.S. Patent No. 10,987,654 under Title 35 of the United States Code.
-
What is the significance of U.S. Patent No. 10,987,654?
The '654 patent covers specific aspects of a pharmaceutical formulation and its method of preparation, providing Impax Laboratories with exclusive rights to that technology for a defined period.
-
Has Ascent Pharmaceuticals responded to the allegations?
As of the filing date of August 27, 2024, Ascent Pharmaceuticals has not yet filed a formal response to the complaint.
-
What is the estimated timeline for this litigation?
Pharmaceutical patent litigation, especially under the Hatch-Waxman framework, can be protracted, often lasting 18 to 36 months or longer, depending on the complexity of the issues and the willingness of parties to settle.
-
What are the potential financial consequences for Ascent Pharmaceuticals if found liable?
If found liable for infringement, Ascent Pharmaceuticals could face substantial financial penalties, including lost profits for Impax Laboratories, reasonable royalties, and potentially treble damages if infringement is deemed willful.
Citations
[1] Complaint for Patent Infringement, Impax Laboratories, LLC v. Ascent Pharmaceuticals Inc., 2:24-cv-05299 (D.N.J. Aug. 27, 2024).
[2] U.S. Patent No. 10,987,654 (filed Apr. 25, 2021).
